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Abstract 
Background: Numerous treatments strategies were used for Meniere disease (MD). In this study, we aimed to 
compare the efficacy of intratympanic dexamethasone versus intratympanic placebo in intractable MD. 
Methods: This was a single-blinded randomized clinical trial. All patients with Intractable MD underwent 
ventilation tube insertion into tympanic membrane and were randomly allocated to two groups of 18-patients. 
The patients of the first group used dexamethasone base drop (placebo) every other day, the second group used 
dexamethasone drop for 3 months, and all patients were followed for 12 months. 
Results: Control of vertigo and tinnitus with dexamethasone was more than the placebo, but there was no 
statistically significance difference between two groups (P > 0.05). Hearing function improvement and aural 
fullness resolution were higher in the placebo group, but there was no statistically significance difference, too 
(P > 0.05). Vertigo control in dexamethasone group in our study ranged from 72.2% to 83.3% of patients at 
different intervals. These figures ranged from 66.6% to 83.3% in placebo group. The highest rate of hearing 
function improvement in our study was 27.7% in placebo group. Tinnitus also followed the same pattern as 
hearing function. 
Conclusions: Intratympanic dexamethasone for MD is very satisfactory if medical treatment fails with good 
vertigo control and no risk to hearing. 
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Introduction 
Meniere disease (MD) is a disorder the inner ear with a 
set of clinical features including fluctuating hearing 
loss, episodic vertigo, tinnitus, and aural fullness (1). 
MD is associated with endolymphatic hydrops with 
spinning and distention of the membranous, 
endolymph-containing parts of the labyrinthine system. 
The clinical features are subsequent to increased 
hydraulic pressure within the inner ear. This disease is 
idiopathic by definition but it is called MD in case of 
being secondary to various etiologies. These etiologies 
include trauma, endocrine abnormalities, electrolyte 
imbalances, autoimmune dysfunction, medication, 
parasitic infections, and hyperlipidemia (2-4). 
The exact incidence of this condition is hard to 
establish but it is reported from 10 to 150/100000 
persons (5). This condition usually occurs in patients 
between 20 and 40 years old. There is a positive family 
history in 20% of patients which can indicate the role 
of genetic predisposition. Uneven sexual distribution 
has not been reported in the literature (5,6). 
Diagnosis of endolymphatic hydrops is established 
with clinical features (7). There is no specific test 
available for definite diagnosis of MD (8). All the patients 
with a history or clinical features indicating of MD should 
undergo neuro-otologic tests including pure tone 
audiometry (PTA)-tympanometry with acoustic reflex, 
auditory brainstem response, electronystagmography, and 
electrocochleography (9,10). 
The treatment is focused on symptom alleviation 
and prevention of attacks. The majority of patients 
return to normal daily activities with medical 
management (11). Surgical treatment is reserved for 
refractory cases of MD (12,13). New techniques are 
evolving in the treatment of the disease including novel 
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method for delivering medications with higher efficacy 
and less complications. One of the relatively new 
methods is intratympanic injection of medication (14). 
This method is conducted under local anesthesia. 
Advantages of intratympanic injection of steroids 
include less invasiveness, absence of systemic 
complications, providing the ability of prompt 
initiation of treatment, and higher concentration of 
steroids in comparison to oral or intramuscular ways of 
medication prescription. This technique is advised for 
patients who suffer from bilateral MD, who do not 
tolerate general anesthesia and who have good 
compliance for multiple sessions of injection (15). In 
this study, we evaluated the efficacy of intratympanic 
delivery of corticosteroids in intractable cases of MD 
through ventilation tube. 
 
Materials and Methods 
This was a single-blinded randomized clinical trial and 
was conducted from January 2013 through January 
2014 in Tehran University of Medical Sciences 
(TUMS), Amiralam Hospital. All patients with MD 
were advised to have a low-sodium daily diet (daily 
intake of sodium equal to or < 1500 mg). Betahistine 
plus triamtrene-H was prescribed for all patients. On 
occasion, ant vertigo/antiemetic agents were used. This 
regimen was followed for 2 month. If improvement in 
symptoms did not occur, the patients were assigned as 
candidates for intratympanic delivery of 
corticosteroids. All candidates underwent ventilation 
tube insertion under local anesthesia in posterior-
inferior quadrant of tympanic membrane. Patients were 
randomly allocated to two groups of 18-patients using 
block randomization. Patients of the first group used 
dexamethasone base drop (placebo) every other day, 
the second group used dexamethasone drop. All 
patients were unaware of the type of treatment and 
were blinded, but surgeon was not blinded. Subjects 
were instructed to be in the supine position with the 
head rotated 45° toward the contralateral side, keeping 
the treated ear up and not swallow for 20 minutes to 
assure enough time for the medication to be absorbed 
through round window niche. This process lasted for  
3 months. Patients were evaluated on months 1, 3, 6, and 
12 for recording possible improvements in symptoms. 
Auditory tests were conducted in 500, 1000, 2000, 
and 4000 Hz frequencies for all patients. We 
considered 10 dB change in at least 2 frequencies in 
PTA and presence of vertigo as significant findings. 
For all patients, these parameters were measured just 
before treatment initiation and 12 months after 
treatment. All patients were asked about type, 
frequency and duration of vertigo. Tinnitus and aural 
fullness were recorded too. Informed consents were 
obtained from all patients, and the study was approved 
by the Ethics Committee of TUMS and the National 
Medical Ethics Committee considering the Declaration 
of Helsinki. SPSS software (Version 16; SPSS, Inc., 
Chicago, IL, USA) was used for data analysis.  
 
Results 
Patients were recruited for 3 months and after follow-
up sessions, 36 patients completed the study in two 18-
patient groups 16 patients (44.4%) were males while 20 
patients (55.5%) were females. The most frequent age 
group in our study was 30-39 years group. The detailed 
information of sexual distribution, age distribution, and 
disease duration are presented in table 1. 
 
Table 1. Basic characteristics of patients 
Characteristics N (%) 
Gender  
Male 16 (44.4) 
Female 20 (55.5) 
Age (years)  
10-19 2 (5.5) 
20-29 4 (11.1) 
30-39 13 (36.1) 
40-49 8 (22.2) 
50-59 7 (19.4) 
60-69 2 (5.5) 
Disease duration  
0-1 12 (33.3) 
1-2 8 (22.2) 
2-3 6 (16.6) 
3-4 3 (8.3) 
4-5 3 (8.3) 
> 5 4 (11.1) 
 
Vertigo control: In placebo group, vertigo was 
controlled in 15 patients (83.3%) at the first month. In 
further evaluations 13 patients (72.2%), 12 patients 
(66.6%), and 12 patients (66.6%) were vertigo-
controlled at months 3, 6, and 12, respectively. There 
was no case of vertigo worsening detected. 
In dexamethasone group, vertigo was controlled in 
15 patients (83.3%) at the first month. Next follow-ups 
showed 15 (83.3%), 16 (88.8%), and 13 (72.2%) 
vertigo-controlled patients at 3, 6, and 12 months, 
respectively. No case of vertigo worsening was 
detected. There was no statistically significant 
difference between two groups for vertigo control (all 
P > 0.05). Detailed information of vertigo presentation 
is presented in table 2. 
Hearing improvement: In placebo group, hearing 
improved in 3 (16.6%), 3 (16.6%), 4 (22.2%), and 5 
(27.7%) patients at months 1, 3, 6, and 12, respectively. 
In dexamethasone group, hearing improvement was 
seen in 2 (11.1%), 1 (5.5%), 4 (22.2%), and 4 (22.2%) 
patients at months 1, 3, 6, and 12, respectively. There 
was no significant difference seen in hearing 
improvement between two groups (all P > 0.05). 
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Table 2. Vertigo control in two placebo and dexamethasone groups 
Variables 
Dexamethasone group (months) Placebo group (months) 
1 3 6 12 1 3 6 12 
A (%) 2 (11.1) 1 (5.5) 4 (22.2) 4 (22.2) 3 (16.6) 3 (16.6) 4 (22.2) 5 (27.7) 
B1 (%) 11 (61.1) 12 (66.6) 8 (44.4) 5 (27.7) 6 (33.3) 7 (38.3) 4 (22.2) 4 (22.2) 
B2 (%) 2 (11.1) 2 (11.1) 4 (22.2) 4 (22.2) 4 (22.2) 2 (11.1) 3 (16.6) 2 (11.1) 
C (%) 0 0 0 0 2 (22.2) 1 (5.5) 1 (5.5) 1 (5.5) 
D (%) 0 0 0 0 0 0 0 0 
E (%) 3 (16.6) 3 (16.6) 2 (11.1) 5 (27.7) 3 (16.6) 5 (27.7) 6 (33.3) 6 (33.3) 
F (%) 0 0 0 0 0 0 0 0 
A: At least 10 dB improvement in comparison to the best hearing threshold before treatment + absence of recurrent vertigo; B1: No change in hearing 
threshold in comparison to the best hearing threshold before treatment + absence of recurrent vertigo; B2: Hearing threshold between the best and the 
worst hearing threshold before treatment + absence of recurrent vertigo; C: Hearing threshold equal to the worst hearing threshold before treatment + 
absence of recurrent vertigo; D: Hearing threshold worse than the worst hearing threshold before treatment + absence of recurrent vertigo; E: A or B 
criteria + recurrent vértigo; F: C or D criteria + recurrent vertigo 
 
Tinnitus control: In placebo group, tinnitus 
improvement was in 1 patient (9%) and 1 patient (9%) 
at months 6 and 12, respectively. In dexamethasone 
group, improvement was seen in 1 (7.1%), 2 (14.2%),  
2 (14.2%), and 4 (28.4%) patients at months 1, 3, 6, 
and 12, respectively. There was no significant 
difference in tinnitus control between two groups (all  
P > 0.05) (Table 3). 
Aural fullness: In placebo group, aural fullness was 
decreased from 8 (100%) patients at baseline to 1 
patient (12.5%) at month 12. In dexamethasone group, 
there was no aural fullness at month 12. There was no 
significant difference found between two groups for 
aural fullness (P > 0.05). Detailed information is seen 
at table 4. 
Complications: There was just one case of chronic 
infection with tympanic membrane perforation without 
resolution after treatment, which was underwent 
tympanoplasty surgery. 
 
Discussion 
Our study showed that control of vertigo and tinnitus 
with dexamethasone was more than the placebo, but 
there was no statistically significance difference 
between two groups. Hearing function improvement 
and aural fullness resolution were higher in the placebo 
group, but there was no statistically significance 
difference, too. 
The causes of MD are not thoroughly understood 
yet. Due to this lack of knowledge on definite 
underlying cause of the disease, various therapeutic 
approaches have developed including intratympanic 
steroid injection, intratympanic gentamicin injection, 
endolymph sac decompression, vestibular neurectomy, 
and labyrinthectomy surgery. 
However, some reports have acclaimed the role of 
viral infections and autoimmune components in the MD 
development. The idea of immune basis of Meniere was 
first introduced by Ryan (16) afterward; there was a 
growing bulk of evidence indicating various aspects of 
autoimmune activity in MD. Reports of higher levels of 
antibodies against antigens of inner ear (6,17-21) and 
higher incidence of other autoimmune diseases in MD 
patients (22-24) emphasize the role of autoimmune 
processes in the development of MD. These pieces of 
evidence provide rationale for administration of steroids 
in the treatment of MD. Systemic steroids are used widely 
and easily but long-term complications raise concerns 
about abundant prescription of these agents for MD, so 
the idea of intratympanic delivery of steroids was 
developed. This method with the same basis was 
performed in different ways. Middle ear injection, 
labyrinth perfusion after myringotomy with laser and 
ventilation tube insertion have been some types of this 
method. Using intratympanic steroid in topical from 
through ventilation tube seems feasible and practical (25). 
Vertigo control in dexamethasone group in our 
study ranged from 72.2% to 83.3% of patients at 
different intervals. These figures ranged from 66.6% to 
83.3% in placebo group. Itoh and Sakata (26) found 
similar results with intratympanic injection of 
dexamethasone. A systematic review on efficacy of 
intratympanic steroids in controlling symptoms of MD 
reported that 90% improvement in vertigo symptom 
was seen (15). 
 
Table 3. Tinnitus status in two groups of placebo and dexamethasone treatment 
Variables 
Dexamethasone group (months) Placebo group (months) 
1 3 6 12 1 3 6 12 
None (%) 5 (27.7) 6 (33.3) 6 (33.3) 8 (44.4) 7 (38.8) 7 (38.8) 8 (44.4) 8 (44.4) 
Mild (%) 8 (44.4) 7 (38.8) 9 (50) 7 (38.8) 5 (27.7) 8 (44.4) 8 (44.4) 8 (44.4) 
Moderate (%) 5 (27.7) 4 (22.2) 1 (5.5) 2 (11.1) 6 (33.3) 3 (16.6) 2 (11.1) 2 (11.1) 
Severe (%) 0 1 (5.5) 2 (11.1) 0 0 0 0 0 
Worst attack ever (%) 0 0 0 1 (5.5) 0 0 0 0 
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Table 4. Aural fullness frequency in two groups of placebo and dexamethasone treatment 
Parameter Baseline 
Dexamethasone group (months) 
Baseline 
Placebo group (months) 
1 3 6 12 1 3 6 12 
Frequency (%) 8 (100) 0 0 1 (12.5) 0 8 (100) 0 2 (25) 0Q 1 (12.5) 
 
Montandon et al. (27) reported that ventilation tube 
decreased vertigo attacks from 71% to 11% with its 
placebo effect. This finding is consistent with our 
findings which strongly suggest placebo effect of 
ventilation tube insertion. 
The highest rate of hearing function improvement 
in our study was 27.7% in placebo group. Our findings 
regarding hearing function improvement are not as 
high as previous studies. Shea and Ge (28) reported a 
68% improvement in hearing; Silverstein et al. (29) 
also reported a 43% improvement rate. Garduno-Anaya 
et al. (30) findings are near our study with 35% 
improvement in hearing function. Tinnitus follows the 
same pattern; while in our study, tinnitus showed 
maximum improvement rate of 28.4%, other reports 
declare rates around 45-82 percent. 
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